Comparison of the Analgesic Efficacy and Tolerability of Tramadol 100mg Sustained-Release Tablets and Tramadol 50mg Capsules for the Treatment of Chronic Low Back Pain
This multicentre, randomised, double-blind, parallel-group study was designed to examine the analgesic efficacy and tolerability of a newly developed tramadol slow-release (SR) tablet in comparison with immediate-release tramadol capsules in patients with chronic low back pain which had persisted despite intervention with other pharmacological and/or nonpharmacological measures. 103 patients were treated with tramadol SR tablets twice daily (2 × 100 mg/day) and 102 patients with capsules 4 times daily (4 × 50 mg/day) over a period of 3 weeks. The medication in both groups (verum/placebo) was administered 4 times daily to ensure the double-blind character of the study (‘double-dummy technique’). In case of insufficient pain relief the patients received 2 × 200mg SR/day as an escape medication (open design). Daily pain intensity was assessed by patients on a 4-step verbal rating scale. At the end of the study retrograde assessment of analgesia was done by the patient using a 5-step classification. Sufficient pain relief could be achieved in approximately 60% of the patients (116 patients) who completed the 3-week treatment period. There was no difference in pain relief (SR 59% and capsules 59%) and in course of pain intensity between both groups. Furthermore, 30 patients (15.3%) were satisfactorily treated with the escape medication. Adverse events were reported at a similar rate in both groups (54.4% with the SR tablet formulation and 52.9% with the capsules). The main adverse events were nausea (16.6%), dizziness (14.1%), vomiting (9.8%), tiredness (7.8%), diaphoresis (6.3%), headache (6.3%), constipation (6.3%) and dry mouth (6.3%). With the exception of diaphoresis, constipation and dry mouth, adverse events decreased in incidence during the study. The results confirmed the equivalence with regard to efficacy and tolerability of twice-daily administration of tramadol SR tablets compared with 4-times-daily administration of tramadol capsules.
KeywordsAdis International Limited Tramadol Drug Invest Chronic Back Pain Verbal Rating Scale
Unable to display preview. Download preview PDF.
- 5.Anderson A, Kohnen C, Cossmann M. Behandlung mäßig starker bis starker Schmerzen: multizentrsiche Anwendungs-beochtuang des Analgetikums Tramal. Kassenarzt 1994; 40: 44–54Google Scholar
- 6.Barkin RL. Focus on tramadol: a centrally acting analgesic for moderate to moderately severe pain. Formulary 1995; 30: 321–5Google Scholar
- 8.Osipova NA, Novikov GA, Beresnev VA, et al. Analgesic effect of tramadol in cancer patients with chronic pain: a comparison with prolonged-action morphine sulfate. Curr Ther Res 1991; 50(6): 812–21Google Scholar
- 12.Cossmann M, Wilsmann KM. Treatment of prolonged pain. Assessment of the efficacy and safety of repeated administration of tramadol (Tramal®). Münch Med Wochenschr 1987; 129(46): 851–4Google Scholar
- 15.Ladurner G, Griebnitz E. Bandscheiben-Schäden, konservativ behandelt I + II. Ärztl Praxis 1990; 42(41): 20–4Google Scholar
- 16.Bird HA, Hill J, Stratford ME, et al. A double-blind crossover study comparing the analgesic efficacy of tramadol with pentazocine in patients with osteoarthritis. J Drug Dev Clin Prac 1995; 7: 181–8Google Scholar
- 20.Sommer F. Klinische Prüfung mit dem Analgetikum Tramadol-HCl. Erfahrungsbericht aus einer orthopädischen Praxis. Extr Med Pract 1981; 2(9): 826–31Google Scholar
- 22.Grond S, Zech D, Lynch J, et al. Tramadol — a weak opioid for relief of cancer pain. Pain Clin 1992; 5(4): 241–7Google Scholar
- 23.Data on file. Grünenthal Report FO-PK 383Google Scholar